10.24.25 -- STREAM Edition: Using PATs For Real-Time Process Monitoring

Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, discusses the company's efforts to streamline its operations to focus on fewer assets with high potential, particularly short-duration psychedelics. Over the next year, the company anticipates four key Phase 2 readouts, which will be critical in shaping its next phase of growth.

This presentation discusses the shift in pharmaceuticals from small-molecule drugs to protein biologics and the associated challenges, particularly the immunogenic response.

4C Associates' Tom Wells discusses the concept of "Payment Share" or "Bonus-Malice" in procurement, where suppliers' compensation is directly tied to outcomes. While acknowledging it’s potential, he highlights the challenge in biotech due to numerous uncontrollable variables that can impact a drug's success beyond the supplier's direct influence.

In this segment from the Bioprocess Online Live event, “Aligning CMC And MSAT To Move PATs Out Of Pilot Mode,” our panelists respond to results from an audience poll. Audience members indicated they use PATs for real-time process monitoring more in upstream than in downstream. 

 In this episode of “Better Biopharma,” host Tyler Menichiello is joined by OS Therapies’ CEO, Paul Romness, and chief medical and scientific officer, Robert Petit, Ph.D. The three discuss the development and manufacturing of the company’s lead asset, OST-HER2, a Listeria-based immunotherapy for osteosarcoma.

Learn how you can obtain comprehensive solutions for cleanroom projects that help you ensure regulatory compliance and operational efficiency.

Watch to learn about a highly advanced electronic quality management system (QMS) that helps you transform compliance into a competitive advantage.